Twelve-Week 24/7 Ambulatory Artificial Pancreas With Weekly Adaptation of Insulin Delivery Settings: Effect on Hemoglobin A(1c) and Hypoglycemia

OBJECTIVE: Artificial pancreas (AP) systems are best positioned for optimal treatment of type 1 diabetes (T1D) and are currently being tested in outpatient clinical trials. Our consortium developed and tested a novel adaptive AP in an outpatient, single-arm, uncontrolled multicenter clinical trial l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Diabetes Care
Main Authors: Dassau, Eyal, Pinsker, Jordan E., Kudva, Yogish C., Brown, Sue A., Gondhalekar, Ravi, Dalla Man, Chiara, Patek, Steve, Schiavon, Michele, Dadlani, Vikash, Dasanayake, Isuru, Church, Mei Mei, Carter, Rickey E., Bevier, Wendy C., Huyett, Lauren M., Hughes, Jonathan, Anderson, Stacey, Lv, Dayu, Schertz, Elaine, Emory, Emma, McCrady-Spitzer, Shelly K., Jean, Tyler, Bradley, Paige K., Hinshaw, Ling, Laguna Sanz, Alejandro J., Basu, Ananda, Kovatchev, Boris, Cobelli, Claudio, Doyle, Francis J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Diabetes Association 2017
Assuntos:
Emerging Technologies and Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5711334/
https://ncbi.nlm.nih.gov/pubmed/29030383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc17-1188
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados